Australia’s antitrust regulator has launched proceedings against Pfizer’s Australian arm, accusing it of abusing its power when supplying cholesterol-lowering drug atorvastatin to pharmacies.
Novartis has announced it will acquire biotechnology company CoStim for an undisclosed sum.
Baker & McKenzie LLP has added to its IP team with the appointment of Hiroshi Sheraton as partner in its London office.
Humanitarian organisation Médecins Sans Frontières has criticised the US for pressuring the Indian government to review its patent policies.
Myriad and its rival genetic diagnostics company Gene by Gene have agreed to settle their patent infringement case related to BRCA tests.
The US Chamber of Commerce has criticised India’s “recent pattern of pharma patent denials”, which it says “are not about access to medicine”.
Pharmaceutical company Merck and Samsung Bioepis, a joint venture between South Korean firm Samsung and Biogen, have agreed to work on a diabetes treatment.
The US Court of Appeals for the Federal Circuit has upheld a patent covering Pfizer’s pain drug Lyrica, closing the market to any generic challengers until 2018.
Roche’s Indian subsidiary has sued Mylan and Bangalore-based pharmaceutical company Biocon at the Delhi High Court, for launching a biosimilar of its breast cancer drug Herceptin (trastuzumab).
Myriad Genetics has entered into a definitive agreement to acquire inflammatory and autoimmune diagnostics company Crescendo Bioscience for $270 million.